A new rapid and non-invasive test has been developed for detecting early stage glaucoma by researchers at the University of Aberdeen. The test detects abnormalities in visual processing associated with retinal neuropathies such as glaucoma.

About the technology

Worldwide glaucoma is a leading cause of irreversible adult blindness. There is no cure for glaucoma but early diagnosis can allow disease progression to be stopped. Current readily-available optometry tests have a high false positive rate and do not reliably detect early-stage disease. A new rapid and non-invasive test has been developed for detecting early stage glaucoma by researchers at the University of Aberdeen. The test is PC-based and uses the way that humans perceive moving objects to detect abnormalities in visual processing associated with retinal neuropathies such as glaucoma. Performance on the test relates to the degree of neural damage to the retina.

Applications and benefits

Key Benefits: 

  • Specificity and selectivity of test comparable to industry gold standard (Humphrey VFA)
  • Indicates severity of disease stage
  • Potential to detect glaucoma prior to visual field defect

Applications: 

  • Rapid and simple test for glaucoma
  • May be applicable to other retinal neuropathies such as optic neuritis, diabetes and MS
  • Cost-effective mass screening test
  • Addition to other PC-based screening tools
Technology License

Download the Technology Know-How License

For further information, contact

Dr James Duncan, Research & Innovation
Email: James Duncan
Tel: 01224 272918